Olaparib NEW
Price | Get Latest Price |
Package | 1kg |
Min. Order: | 1kg |
Supply Ability: | 10000kg |
Update Time: | 2024-04-13 |
Product Details
Product Name: Olaparib | CAS No.: 763113-22-0 |
EC-No.: 642-941-5 | Min. Order: 1kg |
Purity: 99% | Supply Ability: 10000kg |
Release date: 2024/04/13 |
Manufacturer Provide Best Olaparib Powder Price CAS 763113-22-0 99% Olaparib
Introduction
Product Name: Olaparib
Other Name :4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one
CAS NO:763113-22-0
Purity: 99%min
Appearance:White crystalline powder
Molecular formula:C24H23FN4O3
MW:434.46
Density :1.43
Storage :Keep in dark place,Inert atmosphere,Room temperature
Olaparib is a new type of poly ADP ribose polymerase (PARP) inhibitor, including PARP1, PARP2, and PARP3. PARP mediated a DNA repair mechanism, plays an important role in DNA damage repair and apoptosis, so Ola Pani specific effect on target cell DNA damage repair mechanism, by attacking the carrying BRCA1 and BRCA2 mutation critical vulnerabilities in cancer cells play a role, can be used for breast cancer susceptibility gene (BRCA) mutation and for the maintenance treatment of platinum sensitive recurrent severe ovarian cancer patients.
Application
Olaparib is an anti-tumor targeted therapy drug, which kills cancer cells mainly by synthesizing a lethal mechanism. It is mainly used clinically for the treatment of advanced epithelial ovarian cancer.
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.
Company Profile Introduction
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$31.00/5mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
$1.00/1PCS |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-11-11 | |
$0.00/10g |
VIP3Y
|
HangZhou RunYan Pharma Technology Co.,LTD.
|
2024-09-11 | |
$6.00/1kg |
VIP3Y
|
Hebei Fengjia New Material Co., Ltd
|
2024-09-03 | |
$10.60/1KG |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-20 | |
$0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-07-23 | |
$0.00/25kg |
VIP1Y
|
PUSHAN INDUSTRIAL (SHAANXI) CO.,LTD
|
2024-05-15 | |
$15.00/1kg |
Ouhuang Engineering Materials (Hubei) Co., Ltd
|
2024-04-26 | ||
$1.00/1g |
VIP4Y
|
Dorne Chemical Technology co. LTD
|
2024-03-26 | |
$0.00/1kg |
VIP1Y
|
Shandong Hanjiang Chemical Co., Ltd
|
2024-01-19 |